Published in Clinical Trials Week, June 22nd, 2006
On January 4, 2006, EpiCept completed its merger with Maxim Pharmaceuticals, Inc. The new company combines a relatively lower-risk product pipeline of commercially promising topical pain therapies with the upside potential of a late-stage cancer product and the biopharmaceutical discovery capabilities for apoptosis inducers designed to address unmet medical needs in oncology. On February 7, 2006, EpiCept announced that it raised $11.6 million in gross proceeds through a private placement of common stock and warrants.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.